Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProBioGen Signs Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform

Published: Wednesday, February 20, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology.

The license covers the modification of the pharma’s antibody production platform for the generation of antibodies with enhanced potency. The continued licensing success demonstrates the industry’s endorsement of GlymaxX®. The GlymaxX® technology is highly versatile since it can be applied to any starter or production cell line. It allows both, the robust permanent modification of established antibody expression platforms, as well as the rapid conversion of existing antibody producer clones to produce ADCC-enhanced molecules.

The GlymaxX® technology is based on the stable expression of a heterologous enzyme in the antibody producing cells. GlymaxX® prevents antibody fucosylation almost completely, but moreover allows the exact adjustment of any desired fucosylation level through the controlled addition of fucose into the culture medium.

The license with an option for a commercial license covers the modification of the company’s antibody production platform and the generation of multiple antibodies with enhanced ADCC potency. Financial details are not disclosed.

The technology can be licensed royalty-free, based on milestone-dependent license fees only.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProBioGen, Eucodis Sign Agreement
Company has signed an exclusive license agreement with Eucodis Bioscience to commercialize C-LiNK, a novel antibody drug conjugation technology.
Wednesday, April 20, 2016
ProBioGen and Tizona Therapeutics Sign Agreement
ADCC-enhancement for innovative cancer therapy, produced via ProBioGen’s accelerated CMC development path.
Tuesday, October 06, 2015
ProBioGen Signs GlymaxX ADCC Enhancement Technology License Deal
A non-exclusive commercial multi-product licensing agreement with Novartis.
Tuesday, June 24, 2014
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
GlymaxX® manufacturing technology improves bispecific antibody activity for solid tumor treatment.
Wednesday, March 05, 2014
ProBioGen and Emergent BioSolutions Partner
ProBioGen announces expansion of commercial licenses with Emergent BioSolutions for AGE1.CR® viral vaccine manufacturing production platform.
Tuesday, December 17, 2013
Scientific News
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
Exposure To Routine Viruses Makes Mice Better Test Subjects
Study shows that infections make mouse immune system act more like that in humans.
Immune Booster Tested in Advanced Merkel Cell Cancer
The immunotherapy drug produced durable responses in many patients.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Pandemic E. coli Strain Cloaks its Stealth Strategies
Antibiotic resistance and weakened immunity only partially explain persistent, harmful infection.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!